Jyotsna Singh Vincent, MD
Internal Medicine · Los Gatos
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 24
- 6 carriers
- Offices
- 3
Offices
3 locations · Patricia Sitnitsky PC · UCSF Medical Group Business Services
Looking this up.
Hospitals listed: Mills-Peninsula Medical Center · UCSF Medical Center. That is not proof they admit you there this week.
Plans that list them
24 plans · 6 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Vincent’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
24 of 24 plans
| Alignment Health Advantage PPO (PPO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Prime (HMO-POS) | Anthem Blue Cross Partnership Plan | Listed | Oct 3, 2026 |
| Astiva Health C-SNP WOW - NorCal (HMO C-SNP) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Premier Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Savings Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Blue Shield Inspire (HMO) | Blue Shield of California | Listed | Aug 26, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A141632 · Current
Licensed to practise in California · since 2016 · expires 2027-10-31 · Georgetown University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 75.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Peninsula Medical CenterBurlingame, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.139, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.242, Oct 2024 – Sep 2025
- UCSF Medical CenterSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of UCSF Helen Diller Family Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 81% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 4.9 (3.79 to 6.02) · 7,590 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.8 (11.3 to 14.4) · 2,019 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 139.4 (110.22 to 168.58) · 452 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.622, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.626, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.491, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.7 to 1) · 2,336 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Peninsula Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.139 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.242 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.21 (0.27 to 2.15) · 1,258 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.81 (0.51 to 1.1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 155.44 (112.67 to 198.21) · 90 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.5 · 32 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 82 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10 · 188 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9 · 473 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.8 · 342 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.4 · 485 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 3,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.4) · 6,904 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,052 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.41 (1.43 to 5.39) · 1,695 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.72 (0.17 to 3.28) · 665 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,545 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.1 (1.3 to 12.9) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.96 (2.63 to 9.29) · 653 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.15 to 3.08) · 418 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.14 (0 to 0.78) · 5,539 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.7 · 192 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.215 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.263 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.74 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 300 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19 · 702 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 1.2 · 207 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -13.6 · 531 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 24.3 · 343 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 449 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.5 (2.8 to 7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.6 (6.7 to 13.7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 189 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11 · 45 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.6 · 117 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (9.7 to 17.2) · 584 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 764 cases | No different | Jan 2024 – Dec 2024 |
What patients said (523 patients answered, 27% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 81% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for UCSF Medical Center
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 3 better, 5 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.9 (3.79 to 6.02) · 7,590 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.8 (11.3 to 14.4) · 2,019 cases | Worse | Jan 2024 – Dec 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 139.4 (110.22 to 168.58) · 452 cases | Better | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.622 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.626 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.491 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.7 to 1) · 2,336 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.24 (0.58 to 1.9) · 4,689 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.89 to 1.2) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.9 · 89 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.5 · 85 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.1 · 132 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.6 · 454 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 618 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 380 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.7 · 5,000 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.22 (0.06 to 0.38) · 15,965 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.05 to 0.35) · 17,859 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.85 (0 to 1.83) · 4,184 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2 (1.1 to 2.9) · 6,516 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.35 (4.49 to 10.21) · 3,989 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5 (3.22 to 6.77) · 4,087 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.95 (0.74 to 3.15) · 2,034 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.95 (0.63 to 1.28) · 15,431 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 399 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.899 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.689 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.224 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16 · 156 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20 · 564 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 60.3 · 160 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -9.7 · 550 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 44.1 · 660 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 667 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (4.8 to 6.7) · 2,019 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6 · 421 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.5 · 53 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 107 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.9 (11.3 to 17.1) · 3,247 cases | No different | Jan 2022 – Dec 2024 |
What patients said (3,181 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 71% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 50% |
| "YES", patients would definitely recommend the hospital | 81% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$84,376
Medicare paid this office $84,376 for 243 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 110 | $16,608 | $108 |
| Long return visit (40+ min) | 64 | $14,116 | $162 |
| Short return visit (20+ min) | 118 | $13,582 | $75 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 74 | $11,510 | $156 |
| Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use | 26 | $7,530 | $290 |
See all 15 services
| Return visit (30+ min) | 110 | $16,608 | $108 |
| Long return visit (40+ min) | 64 | $14,116 | $162 |
| Short return visit (20+ min) | 118 | $13,582 | $75 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 74 | $11,510 | $156 |
| Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use | 26 | $7,530 | $290 |
| Sarscv2 vac 30mcg trs-suc im | 24 | $3,528 | $136 |
| Influenza vaccine split virus, preservative free | 28 | $2,271 | $81 |
| Short return visit | 28 | $1,657 | $49 |
| New patient visit (45+ min) | 11 | $1,458 | $133 |
| Annual depression screening, 5 to 15 minutes | 55 | $1,324 | $24 |
| Admn sarscov2 vacc 1 dose | 24 | $1,290 | $50 |
| Administration of influenza virus vaccine | 28 | $1,083 | $39 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 55 | $1,021 | $15 |
| Administration of pneumococcal vaccine | 22 | $851 | $39 |
| Insertion of needle into vein for collection of blood sample | 24 | $216 | $9 |
Who their Medicare patients are
243 Original Medicare patients in 2024. Average age 72 · Under 65 7% · 85 and older 9% · Women 68% · Also on Medicaid 5% · Health risk score 1.11. At or below the middle of the specialty; the typical internal medicine clinician is at 1.76.
Conditions among them: High blood pressure 50% · Cancer 20% · Diabetes 18% · Chronic kidney disease 17% · Depression 16% · Coronary heart disease 14% · Atrial fibrillation 9% · COPD 6% · Heart failure 5%.
The office billed $367,487, Medicare allowed $104,578 and paid $84,376; for 965 services of 29 kinds; $14,617 of it was for drugs given in the office and $69,760 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 243 | 965 | 72 | 1.11 | $367,487 | $84,376 |
| 2023 | 199 | 841 | 73 | 1.07 | $330,532 | $71,696 |
| 2022 | 167 | 2,139 | 72 | 0.99 | $270,438 | $48,504 |
| 2021 | 119 | 386 | 72 | 0.97 | $180,531 | $34,710 |
| 2020 | 23 | 46 | 73 | 1.02 | $24,547 | $4,381 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 13 services
| Long return visit (40+ min) | 69 | $15,223 | $164 |
| Short return visit (20+ min) | 104 | $12,691 | $73 |
| Return visit (30+ min) | 78 | $11,214 | $105 |
| Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use | 31 | $8,736 | $282 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 51 | $7,896 | $155 |
| New patient visit (45+ min) | 22 | $3,023 | $137 |
| New patient visit (60+ min) | 13 | $2,070 | $159 |
| Influenza vaccine split virus, preservative free | 21 | $1,507 | $72 |
| Short return visit | 27 | $1,362 | $49 |
| Administration of pneumococcal vaccine | 30 | $1,102 | $37 |
| Administration of influenza virus vaccine | 21 | $772 | $37 |
| Annual depression screening, 5 to 15 minutes | 20 | $467 | $23 |
| Insertion of needle into vein for collection of blood sample | 25 | $244 | $8 |
2022: 12 services
| Long return visit (40+ min) | 69 | $12,684 | $141 |
| Return visit (30+ min) | 65 | $9,464 | $105 |
| Short return visit (20+ min) | 55 | $5,429 | $73 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 29 | $4,461 | $154 |
| New patient visit (60+ min) | 22 | $3,668 | $167 |
| Pneumococcal vaccine, 23-valent | 15 | $1,974 | $132 |
| New patient visit (45+ min) | 19 | $1,592 | $84 |
| Influenza vaccine split virus, preservative free | 13 | $888 | $68 |
| Administration of pneumococcal vaccine | 18 | $653 | $36 |
| Administration of influenza virus vaccine | 14 | $505 | $36 |
| Annual depression screening, 5 to 15 minutes | 15 | $340 | $23 |
| Insertion of needle into vein for collection of blood sample | 16 | $50 | $3 |
2021: 9 services
| Long return visit (40+ min) | 60 | $13,075 | $166 |
| Return visit (30+ min) | 45 | $6,229 | $111 |
| New patient visit (60+ min) | 36 | $5,434 | $151 |
| Short return visit (20+ min) | 16 | $1,640 | $86 |
| New patient visit (45+ min) | 12 | $1,524 | $127 |
| Pneumococcal vaccine, 23-valent | 12 | $1,505 | $125 |
| Administration of pneumococcal vaccine | 13 | $272 | $21 |
| Administration of influenza virus vaccine | 11 | $230 | $21 |
| Insertion of needle into vein for collection of blood sample | 23 | $81 | $3 |
Drugs they prescribed that Part D paid
$128,196
Pharmacies billed $128,196 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 5% of their Part D prescriptions (100 of 2,177) in 2024. Above the middle of the specialty; the typical internal medicine clinician is at 1%.
1,973 generic and fewer than 11 brand-name prescriptions · $128,196 in drug cost · 31 antibiotic prescriptions to 24 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Eliquis | 20 | $19,265 | $963 |
| Ozempic | 11 | $10,504 | $955 |
| Xarelto | 11 | $5,697 | $518 |
| Atorvastatin | 222 | $2,911 | $13 |
| Synthroid | 20 | $2,568 | $128 |
See all 54 drugs
| Eliquis | 20 | $19,265 | $963 |
| Ozempic | 11 | $10,504 | $955 |
| Xarelto | 11 | $5,697 | $518 |
| Atorvastatin | 222 | $2,911 | $13 |
| Synthroid | 20 | $2,568 | $128 |
| Rosuvastatin | 105 | $2,063 | $20 |
| Wixela Inhub | 19 | $1,603 | $84 |
| Buprenorphine-Naloxone | 12 | $1,418 | $118 |
| Memantine | 14 | $1,314 | $94 |
| Losartan | 106 | $1,172 | $11 |
| Levothyroxine | 95 | $1,119 | $12 |
| Tamsulosin | 44 | $994 | $23 |
| Gabapentin | 55 | $955 | $17 |
| Duloxetine | 27 | $842 | $31 |
| Bupropion Xl | 16 | $758 | $47 |
| Amlodipine Besylate | 91 | $733 | $8 |
| Albuterol Sulfate Hfa | 31 | $649 | $21 |
| Saxagliptin | 12 | $636 | $53 |
| Metformin | 58 | $626 | $11 |
| Valsartan | 12 | $531 | $44 |
| Alendronate | 51 | $524 | $10 |
| Famotidine | 21 | $504 | $24 |
| Pantoprazole | 39 | $489 | $13 |
| Finasteride | 28 | $453 | $16 |
| Acyclovir | 13 | $430 | $33 |
| Lisinopril | 39 | $418 | $11 |
| Fluticasone Propionate | 39 | $392 | $10 |
| Metoprolol | 28 | $337 | $12 |
| Trazodone | 39 | $335 | $9 |
| Oxycodone | 11 | $335 | $30 |
| Escitalopram | 20 | $333 | $17 |
| Acetaminophen-Codeine | 20 | $309 | $15 |
| Omeprazole | 38 | $298 | $8 |
| Allopurinol | 19 | $292 | $15 |
| Carbidopa-Levodopa Er | 12 | $231 | $19 |
| Hydrocodone-Acetaminophen | 29 | $229 | $8 |
| Lisinopril-Hydrochlorothiazide | 16 | $189 | $12 |
| Montelukast | 13 | $169 | $13 |
| Naproxen | 11 | $159 | $14 |
| Ondansetron Odt | 13 | $151 | $12 |
| Carvedilol | 19 | $144 | $8 |
| Pravastatin | 18 | $143 | $8 |
| Hydrochlorothiazide | 24 | $141 | $6 |
| Simvastatin | 11 | $122 | $11 |
| Metformin Hcl Er | 13 | $118 | $9 |
| Clopidogrel | 15 | $116 | $8 |
| Atenolol | 11 | $106 | $10 |
| Citalopram Hbr | 15 | $102 | $7 |
| Morphine Sulfate | 12 | $80 | $7 |
| Cyclobenzaprine | 12 | $42 | $4 |
| Furosemide | 12 | $41 | $3 |
| Alprazolam | 15 | $32 | $2 |
| Lorazepam | 23 | $31 | $1 |
| Tramadol | 19 | $24 | $1 |
Year by year
| 2024 | 2,177 | 251 | 5% (100) | None | $128,196 |
| 2023 | 1,633 | 198 | 7% (109) | None | $76,726 |
| 2022 | 1,155 | 164 | 7% (84) | None | $39,711 |
| 2021 | 612 | 125 | 4% (26) | None | $21,230 |
| 2020 | 919 | 178 | 2% (19) | None | $38,135 |
| 2019 | 1,282 | 206 | 2% (27) | None | $52,791 |
| 2018 | 1,089 | 177 | 3% (28) | None | $36,094 |
| 2017 | 478 | 131 | None | None | $13,893 |
| 2016 | 114 | 47 | None | None | $3,929 |
| 2015 | 20 | None | 0% (0) | None | $680 |
| 2014 | 34 | None | None | None | $2,154 |
| 2013 | 22 | None | None | None | $1,421 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 46 drugs
| Eliquis | 11 | $6,390 | $581 |
| Buprenorphine | 11 | $3,345 | $304 |
| Atorvastatin | 164 | $2,474 | $15 |
| Synthroid | 13 | $1,838 | $141 |
| Rosuvastatin | 57 | $1,609 | $28 |
| Gabapentin | 43 | $1,179 | $27 |
| Duloxetine | 20 | $1,154 | $58 |
| Levothyroxine | 64 | $1,144 | $18 |
| Losartan | 68 | $1,046 | $15 |
| Pregabalin | 21 | $1,008 | $48 |
| Albuterol Sulfate Hfa | 20 | $856 | $43 |
| Pantoprazole | 33 | $755 | $23 |
| Trazodone | 28 | $676 | $24 |
| Tamsulosin | 23 | $657 | $29 |
| Amlodipine Besylate | 56 | $650 | $12 |
| Methylphenidate | 14 | $648 | $46 |
| Bupropion Xl | 13 | $627 | $48 |
| Acyclovir | 17 | $596 | $35 |
| Carbidopa-Levodopa Er | 12 | $576 | $48 |
| Alendronate | 56 | $556 | $10 |
| Metformin | 43 | $525 | $12 |
| Oxycodone | 12 | $449 | $37 |
| Omeprazole | 29 | $403 | $14 |
| Finasteride | 22 | $370 | $17 |
| Lisinopril | 31 | $331 | $11 |
| Escitalopram | 11 | $300 | $27 |
| Hydrochlorothiazide | 36 | $300 | $8 |
| Acetaminophen-Codeine | 20 | $281 | $14 |
| Montelukast | 11 | $281 | $26 |
| Lisinopril-Hydrochlorothiazide | 18 | $277 | $15 |
| Clonidine | 12 | $277 | $23 |
| Hydrocodone-Acetaminophen | 25 | $249 | $10 |
| Fluticasone Propionate | 21 | $215 | $10 |
| Clopidogrel | 12 | $207 | $17 |
| Alprazolam | 17 | $202 | $12 |
| Citalopram Hbr | 20 | $202 | $10 |
| Cyclobenzaprine | 15 | $195 | $13 |
| Carvedilol | 13 | $186 | $14 |
| Simvastatin | 13 | $184 | $14 |
| Sertraline | 11 | $164 | $15 |
| Ketoconazole | 11 | $159 | $14 |
| Sumatriptan | 11 | $141 | $13 |
| Lorazepam | 19 | $117 | $6 |
| Ondansetron Odt | 13 | $97 | $7 |
| Morphine Sulfate | 15 | $78 | $5 |
| Tramadol | 17 | $58 | $3 |
2022: 27 drugs
| Pregabalin | 18 | $1,862 | $103 |
| Levothyroxine | 56 | $1,168 | $21 |
| Duloxetine | 13 | $1,156 | $89 |
| Atorvastatin | 104 | $1,112 | $11 |
| Rosuvastatin | 29 | $919 | $32 |
| Gabapentin | 29 | $781 | $27 |
| Losartan | 45 | $767 | $17 |
| Trazodone | 26 | $560 | $22 |
| Cyclobenzaprine | 11 | $466 | $42 |
| Alprazolam | 21 | $447 | $21 |
| Hydrochlorothiazide | 40 | $445 | $11 |
| Amlodipine Besylate | 66 | $345 | $5 |
| Hydrocodone-Acetaminophen | 19 | $321 | $17 |
| Oxycodone | 12 | $295 | $25 |
| Morphine Sulfate Er | 12 | $291 | $24 |
| Fluticasone Propionate | 16 | $256 | $16 |
| Lisinopril-Hydrochlorothiazide | 12 | $205 | $17 |
| Alendronate | 16 | $204 | $13 |
| Tamsulosin | 12 | $195 | $16 |
| Metformin | 31 | $173 | $6 |
| Lisinopril | 22 | $168 | $8 |
| Montelukast | 13 | $163 | $13 |
| Escitalopram | 12 | $151 | $13 |
| Omeprazole | 16 | $148 | $9 |
| Ondansetron Odt | 11 | $96 | $9 |
| Lorazepam | 15 | $65 | $4 |
| Losartan-Hydrochlorothiazide | 11 | $55 | $5 |
2021: 14 drugs
| Levothyroxine | 30 | $737 | $25 |
| Atorvastatin | 49 | $631 | $13 |
| Rosuvastatin | 11 | $613 | $56 |
| Alprazolam | 20 | $530 | $26 |
| Gabapentin | 12 | $385 | $32 |
| Morphine Sulfate Er | 13 | $355 | $27 |
| Amlodipine Besylate | 36 | $263 | $7 |
| Escitalopram | 12 | $220 | $18 |
| Losartan | 27 | $214 | $8 |
| Pantoprazole | 12 | $210 | $18 |
| Lisinopril | 20 | $177 | $9 |
| Hydrochlorothiazide | 19 | $150 | $8 |
| Tamsulosin | 12 | $116 | $10 |
| Metformin | 14 | $73 | $5 |
2020: 23 drugs
| Alvesco | 17 | $1,959 | $115 |
| Levothyroxine | 48 | $1,288 | $27 |
| Atorvastatin | 65 | $1,150 | $18 |
| Ventolin Hfa | 18 | $997 | $55 |
| Amlodipine Besylate | 47 | $530 | $11 |
| Lisinopril | 44 | $517 | $12 |
| Pravastatin | 14 | $500 | $36 |
| Hydrochlorothiazide | 40 | $423 | $11 |
| Losartan | 35 | $413 | $12 |
| Escitalopram | 11 | $390 | $35 |
| Atenolol | 31 | $350 | $11 |
| Simvastatin | 29 | $338 | $12 |
| Fluticasone Propionate | 21 | $313 | $15 |
| Omeprazole | 15 | $301 | $20 |
| Gabapentin | 11 | $237 | $22 |
| Famotidine | 27 | $215 | $8 |
| Lisinopril-Hydrochlorothiazide | 17 | $187 | $11 |
| Metoprolol | 17 | $175 | $10 |
| Montelukast | 17 | $170 | $10 |
| Metformin Hcl Er | 20 | $167 | $8 |
| Metformin | 15 | $164 | $11 |
| Lovastatin | 13 | $158 | $12 |
| Pantoprazole | 11 | $153 | $14 |
2019: 30 drugs
| Atorvastatin | 92 | $2,385 | $26 |
| Levothyroxine | 70 | $1,973 | $28 |
| Fluocinonide | 17 | $1,828 | $108 |
| Ventolin Hfa | 31 | $1,619 | $52 |
| Lisinopril | 67 | $809 | $12 |
| Amlodipine Besylate | 59 | $648 | $11 |
| Atenolol | 47 | $567 | $12 |
| Losartan | 36 | $523 | $15 |
| Omeprazole | 27 | $517 | $19 |
| Pravastatin | 16 | $500 | $31 |
| Acetaminophen-Codeine | 22 | $488 | $22 |
| Hydrochlorothiazide | 45 | $480 | $11 |
| Gabapentin | 17 | $465 | $27 |
| Simvastatin | 38 | $432 | $11 |
| Fluticasone Propionate | 25 | $398 | $16 |
| Alendronate | 21 | $345 | $16 |
| Lovastatin | 25 | $326 | $13 |
| Lisinopril-Hydrochlorothiazide | 29 | $315 | $11 |
| Duloxetine | 12 | $236 | $20 |
| Metoprolol | 24 | $221 | $9 |
| Metformin | 22 | $218 | $10 |
| Pantoprazole | 15 | $214 | $14 |
| Famotidine | 16 | $207 | $13 |
| Naproxen | 17 | $206 | $12 |
| Bupropion Xl | 11 | $200 | $18 |
| Glipizide | 13 | $157 | $12 |
| Losartan-Hydrochlorothiazide | 14 | $154 | $11 |
| Metformin Hcl Er | 17 | $147 | $9 |
| Alprazolam | 12 | $94 | $8 |
| Lorazepam | 11 | $66 | $6 |
2018: 28 drugs
| Atorvastatin | 89 | $2,439 | $27 |
| Fluocinonide | 16 | $2,045 | $128 |
| Levothyroxine | 46 | $1,351 | $29 |
| Ventolin Hfa | 19 | $935 | $49 |
| Losartan | 36 | $618 | $17 |
| Lisinopril | 57 | $602 | $11 |
| Gabapentin | 14 | $597 | $43 |
| Pravastatin | 15 | $493 | $33 |
| Omeprazole | 29 | $464 | $16 |
| Atenolol | 33 | $386 | $12 |
| Pantoprazole | 19 | $379 | $20 |
| Lovastatin | 30 | $336 | $11 |
| Terazosin | 11 | $320 | $29 |
| Amlodipine Besylate | 37 | $312 | $8 |
| Simvastatin | 27 | $307 | $11 |
| Fluticasone Propionate | 18 | $307 | $17 |
| Hydrochlorothiazide | 28 | $303 | $11 |
| Metformin | 25 | $258 | $10 |
| Metoprolol | 26 | $245 | $9 |
| Ondansetron | 15 | $236 | $16 |
| Duloxetine | 11 | $204 | $19 |
| Acetaminophen-Codeine | 12 | $189 | $16 |
| Acyclovir | 12 | $185 | $15 |
| Glipizide | 17 | $169 | $10 |
| Naproxen | 14 | $164 | $12 |
| Lisinopril-Hydrochlorothiazide | 14 | $159 | $11 |
| Metformin Hcl Er | 12 | $137 | $11 |
| Alprazolam | 13 | $114 | $9 |
2017: 13 drugs
| Atorvastatin | 41 | $1,092 | $27 |
| Ventolin Hfa | 15 | $680 | $45 |
| Levothyroxine | 27 | $590 | $22 |
| Lisinopril | 36 | $427 | $12 |
| Losartan | 12 | $332 | $28 |
| Pantoprazole | 15 | $299 | $20 |
| Atenolol | 21 | $265 | $13 |
| Naproxen | 15 | $201 | $13 |
| Hydrochlorothiazide | 14 | $150 | $11 |
| Amlodipine Besylate | 17 | $148 | $9 |
| Lovastatin | 11 | $142 | $13 |
| Simvastatin | 11 | $129 | $12 |
| Metoprolol | 11 | $108 | $10 |
2016: 2 drugs
| Levothyroxine | 13 | $224 | $17 |
| Amlodipine Besylate | 11 | $71 | $6 |
Money from drug and device companies
$158 in 2025
| 2025 | 6 | 7 | None | $158 |
| 2021 | 1 | 1 | None | $35 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Pfizer | Nurtec Odt | $50 | 2 payments
|
| Lundbeck | Vyepti | $26 | 1 payment
|
| Lilly USA | Kisunla | $22 | 1 payment
|
| Otsuka America Pharmaceutical | Rexulti | $22 | 1 payment
|
| Invivyd | Pemgarda | $21 | 1 payment
|
| ViiV Healthcare | Apretude | $17 | 1 payment
|
See all 7 published payments
| Otsuka America Pharmaceutical | Meals · 2025-12-09 | Rexulti | $22 |
| Pfizer | Meals · 2025-11-11 | Nurtec Odt | $27 |
| Invivyd | Meals · 2025-11-04 | Pemgarda | $21 |
| Pfizer | Meals · 2025-10-27 | Nurtec Odt | $23 |
| ViiV Healthcare | Meals · 2025-10-22 | Apretude | $17 |
| Lundbeck | Meals · 2025-09-23 | Vyepti | $26 |
| Lilly USA | Meals · 2025-09-15 | Kisunla | $22 |
See earlier years (2021)
2021: $35
| Edwards Lifesciences | Edwards Sapien 3 Ultra Transcatheter Heart Valve | $35 | 1 payment
|
Professional record
- NPI
- 1427316835
- Licence
- CA A141632California A141632: Current · expires 2027-10-31
- Trained
- Georgetown University School of Medicine, 2012
- Group
- Patricia Sitnitsky PC · UCSF Medical Group Business Services
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Internal medicine (207R00000X)
- Mailing address
- 827 Altos Oaks Dr Ste 4, Los Altos, CA, 94024
- NPI first listed
- 2012-04-24
- NPI last updated
- 2025-09-10
- NPI record certified
- 2025-09-10
This is when the NPI record was last certified, not a medical board exam.